Free Republic

INOVIO's Pan-SARS-CoV-2 vaccine candidate INO-4802 is not matched to a single variant, unlike other variant vaccines in development; INO-4802 could potentially offer broader immune responsesPhase 1/2 clinical trials with INO-4802 are planned this yearINOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant) in preclinical models. These...

Pharmaceutical giant Johnson & Johnson is partnering with the U.S. government to produce up to 1 billion doses of a coronavirus vaccine for use around the world by the end of next year. Asked on NBC’s “Today” on Monday how quickly the first vaccines could be available, CEO Alex Gorsky replied, “This is like a moonshot for us.” “What would usually take five to seven years, we expect to be able to accomplish in five to seven months,” he said. ------------ SNIP ------------ SEE BELOW FOR IMPORTANT RELATED INFORMATION